Mannose Receptor C Type 2 Predicts Poor Outcome in Glioma and is Associated With Invasive Phenotypes and β-Catenin/EMT-related Changes
Journal of Visualized Experiments · 2026
DOI: 10.3791/70882 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Yanni Yu and 7 co-authors. Institution: Medical school Vocational Technical College Yueyang. Major MEDLINE topics: Glioma, beta Catenin, Receptors, Cell Surface, Brain Neoplasms. 43 references.
Abstract (original language)
Glioma remains a lethal malignancy of the central nervous system, and additional biomarkers that improve prognostic stratification and inform therapeutic exploration are still needed. This study evaluated mannose receptor C-type 2 (MRC2/Endo180) by integrating public transcriptomic cohorts with in vitro validation. Expression profiles and matched clinical annotations were obtained from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project for tumor-normal comparisons and pan-cancer screening, and prognostic associations were further examined in the Chinese Glioma Genome Atlas (CGGA) cohort. MRC2 expression was assessed in glioma cell lines by reverse transcription quantitative PCR (RT-qPCR) and immunoblotting, and stable MRC2 knockdown was established in U87 and U251 cells using lentiviral short hairpin RNAs (shRNAs). Cell growth and clonogenicity were evaluated using CCK-8 and colony formation assays, whereas migration and invasion were assessed using porous-membrane insert assays. CDK4, CDK6, and β-catenin/epithelial-mesenchymal transition (EMT)-related markers were analyzed by immunoblotting. Across datasets, MRC2 was elevated in glioma, and higher expression was associated with worse overall survival, disease-specific survival, and progression-free interval. In vitro, MRC2 depletion reduced proliferation, clonogenicity, migration, and invasion, accompanied by decreased CDK4 and CDK6 protein levels and changes in β-catenin and EMT-related markers. Together, these findings support MRC2 as a candidate prognostic biomarker associated with aggressive glioma phenotypes and warrant further mechanistic and in vivo investigation.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Medical school Vocational Technical College Yueyang.
- Department of Ultrasound Medicine, Nanfang Hospital, Southern Medical University.
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University.
- Science Research Center, Huizhou Central People's Hospital; School of Public Health, Benedictine University.
- Science Research Center, Huizhou Central People's Hospital; tufmmu@188.com.
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University; 13991998909@163.com.
Cite
APA
Yu, Y., Ji, L., Li, J., Tian, Y., Wang, Z., Tu, Y., Zhen, H., & Xu, L. (2026). Mannose Receptor C Type 2 Predicts Poor Outcome in Glioma and is Associated With Invasive Phenotypes and β-Catenin/EMT-related Changes. Journal of Visualized Experiments. https://doi.org/10.3791/70882
Vancouver
Yu Y, Ji L, Li J, Tian Y, Wang Z, Tu Y, et al. Mannose Receptor C Type 2 Predicts Poor Outcome in Glioma and is Associated With Invasive Phenotypes and β-Catenin/EMT-related Changes. Journal of Visualized Experiments. 2026. doi:10.3791/70882
BibTeX
@article{Yu2026,
author = {Yu, Yanni and Ji, Lijing and Li, Juan and Tian, Yu and Wang, Zhiwen and Tu, Yanyang and Zhen, Haining and Xu, Lei},
title = {Mannose Receptor C Type 2 Predicts Poor Outcome in Glioma and is Associated With Invasive Phenotypes and β-Catenin/EMT-related Changes},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/70882}
}
EUVIMED